

Maraviroc plus Raltegravir ROCnROL (ANRS 157) Trial

Maraviroc + Raltegravir ROCnRal (ANRS 157): Study Design

Study Design: ROCnRAL (ANRS 157)


• **Background**: Pilot, phase II, single-arm trial to evaluate capacity of a dual regimen of raltegravir plus maraviroc to maintain viral suppression in virally suppressed adults with HIV who have hyperlipidemia.

• Inclusion Criteria (n = 44)

- Adults
- On ART for ≥5 years
- Naïve to INSTIs and maraviroc
- HIV RNA <200 copies/mL x 24 months and
 <50 copies/mL for ≥12 months
- R5 tropism

Switch Treatment Arm


- Raltegravir 400 mg BID + Maraviroc 300 mg BID





Maraviroc + Raltegravir ROCnRal (ANRS 157): Result


Week 24 Virologic Response





Maraviroc + Raltegravir ROCnRal (ANRS 157): Result


Analysis of Lipids on Dual Therapy (Median time = 19.4 weeks)





Maraviroc + Raltegravir ROCnRal (ANRS 157): Result

Change in Bone Mineral Density from Baseline (Median interval: 26 wks)





Maraviroc + Raltegravir ROCnRal (ANRS 157): Conclusions

Conclusions: "In long-term-experienced patients, maraviroc/raltegravir therapy lacks virological robustness despite a benefit in lipid profile and bone density."



Acknowledgment

The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.



